Nothing said here yet.
to join the conversation.
| Duffy Sean P.Chief Executive Officer | Sell | 12,944 | $266.8K | Thu, Oct 1 |
| Duffy Sean P.Chief Executive Officer | Sell | 4,314 | $90.2K | Thu, Oct 1 |
| Duffy Sean P.Chief Executive Officer | Sell | 13,560 | $295.6K | Thu, Sep 10 |
| Cook Steven L.Chief Financial Officer | Sell | 6,200 | $135.1K | Thu, Sep 10 |
| Shao Wei-LiPresident | Sell | 3,636 | $79.2K | Thu, Sep 10 |
| Duffy Sean P.Chief Executive Officer | Sell | 1,400 | $31.6K | Thu, Sep 10 |
| Cook Steven L.Chief Financial Officer | Sell | 600 | $13.5K | Thu, Sep 10 |
| Shao Wei-LiPresident | Sell | 400 | $9.0K | Thu, Sep 10 |
| Gracey CraigChief Accounting Officer | Sell | 644 | $14.0K | Wed, Sep 9 |
| Duffy Sean P.Chief Executive Officer | Sell | 7,344 | $169.8K | Tue, Sep 1 |
| Duffy Sean P.Chief Executive Officer | Sell | 5,600 | $135.9K | Tue, Sep 1 |
| Duffy Sean P.Chief Executive Officer | Sell | 4,933 | $114.1K | Tue, Sep 1 |
Omada Health (OMDA) drew fresh attention after its recent share price slide, with the stock down about 6% over the past month and roughly 11% over the past 3 months.
Despite selling over 9,000 shares, the insider still holds 307,372 shares.
Duffy exercised options at $9.18 per share and sold under a pre-established Rule 10b5-1 trading plan adopted in March, maintaining over 1.2 million shares through direct and indirect holdings.
Revenue surged 43% to $88 million as margins expanded and guidance rose.
Omada Health (NASDAQ:OMDA) highlighted record second-quarter revenue and margin performance at the Canaccord Genuity Growth Conference, while outlining its strategy to expand across cardiometabolic conditions, deepen channel partnerships and use GLP-1-related…
Omada Health (OMDA) drew investor attention on 6 August 2026 after reporting record second quarter results, raising full year 2026 guidance, and outlining a planned CEO transition effective 1 January 2027. See our latest analysis for Omada Health.